Bioventus Inc. (BVS) income statement
BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 27, 2026Last filing: 10-Q on Nov 2, 2026Score 13/3041% below fair value
$10.60+0.14 (+1.34%)
Close on Nov 17, 2026Market cap $891.37MP/E 13.8Yield –
Bioventus Inc. income statement
Ratios
Latest available, balances at Jun 27, 2026
Profitability, TTM
- Gross margin
- 68.7%
- Operating margin
- 10.0%
- Net margin
- 9.4%
- Return on equity, FY2025
- 13.7%
Financial strength
- Current ratio
- 1.69
- Debt to equity
- 1.09
- Debt to assets
- 36.9%
- Cash to current liabilities
- 19.3%
Valuation
- P/E ratio
- 13.8
- Price to sales
- 1.53
- Price to book
- 3.90
- Dividend yield
- –
See a number that looks wrong?